vs

Side-by-side financial comparison of ACACIA RESEARCH CORP (ACTG) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

ACACIA RESEARCH CORP is the larger business by last-quarter revenue ($50.1M vs $27.6M, roughly 1.8× Zymeworks Inc.). ACACIA RESEARCH CORP runs the higher net margin — 6.8% vs -71.0%, a 77.8% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 2.6%).

Acacia Research Corporation is a publicly traded American company based in New York City. It acquires and operates businesses in industries including the technology, energy, and industrial/manufacturing sectors. Acacia has a strategic relationship with Starboard Value, LP, the company's controlling shareholder. The company has been characterized as a patent troll.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

ACTG vs ZYME — Head-to-Head

Bigger by revenue
ACTG
ACTG
1.8× larger
ACTG
$50.1M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+70.0% gap
ZYME
72.6%
2.6%
ACTG
Higher net margin
ACTG
ACTG
77.8% more per $
ACTG
6.8%
-71.0%
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ACTG
ACTG
ZYME
ZYME
Revenue
$50.1M
$27.6M
Net Profit
$3.4M
$-19.6M
Gross Margin
12.8%
Operating Margin
-26.1%
-80.1%
Net Margin
6.8%
-71.0%
Revenue YoY
2.6%
72.6%
Net Profit YoY
125.5%
34.3%
EPS (diluted)
$0.03
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACTG
ACTG
ZYME
ZYME
Q4 25
$50.1M
Q3 25
$59.4M
$27.6M
Q2 25
$51.2M
$48.7M
Q1 25
$124.4M
$27.1M
Q4 24
$48.8M
$31.0M
Q3 24
$23.3M
$16.0M
Q2 24
$25.8M
$19.2M
Q1 24
$24.3M
$10.0M
Net Profit
ACTG
ACTG
ZYME
ZYME
Q4 25
$3.4M
Q3 25
$-2.7M
$-19.6M
Q2 25
$-3.3M
$2.3M
Q1 25
$24.3M
$-22.6M
Q4 24
$-13.4M
$-23.5M
Q3 24
$-14.0M
$-29.9M
Q2 24
$-8.4M
$-37.7M
Q1 24
$-186.0K
$-31.7M
Gross Margin
ACTG
ACTG
ZYME
ZYME
Q4 25
12.8%
Q3 25
21.2%
Q2 25
12.8%
Q1 25
47.4%
Q4 24
17.6%
Q3 24
10.1%
Q2 24
26.2%
Q1 24
49.2%
Operating Margin
ACTG
ACTG
ZYME
ZYME
Q4 25
-26.1%
Q3 25
-10.8%
-80.1%
Q2 25
-24.2%
-1.4%
Q1 25
30.8%
-94.5%
Q4 24
-32.4%
-71.6%
Q3 24
-44.1%
-213.8%
Q2 24
-18.4%
-222.9%
Q1 24
-8.6%
-376.9%
Net Margin
ACTG
ACTG
ZYME
ZYME
Q4 25
6.8%
Q3 25
-4.6%
-71.0%
Q2 25
-6.4%
4.8%
Q1 25
19.5%
-83.5%
Q4 24
-27.5%
-75.8%
Q3 24
-60.0%
-186.6%
Q2 24
-32.7%
-195.8%
Q1 24
-0.8%
-315.6%
EPS (diluted)
ACTG
ACTG
ZYME
ZYME
Q4 25
$0.03
Q3 25
$-0.03
$-0.26
Q2 25
$-0.03
$0.03
Q1 25
$0.25
$-0.30
Q4 24
$-0.14
$-0.32
Q3 24
$-0.14
$-0.39
Q2 24
$-0.08
$-0.49
Q1 24
$0.00
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACTG
ACTG
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$306.7M
$64.8M
Total DebtLower is stronger
$91.9M
Stockholders' EquityBook value
$543.5M
$320.1M
Total Assets
$771.0M
$397.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACTG
ACTG
ZYME
ZYME
Q4 25
$306.7M
Q3 25
$301.8M
$64.8M
Q2 25
$316.7M
$98.3M
Q1 25
$272.0M
$76.2M
Q4 24
$273.9M
$66.1M
Q3 24
$410.9M
$122.4M
Q2 24
$441.9M
$71.0M
Q1 24
$498.4M
$114.8M
Total Debt
ACTG
ACTG
ZYME
ZYME
Q4 25
$91.9M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACTG
ACTG
ZYME
ZYME
Q4 25
$543.5M
Q3 25
$537.6M
$320.1M
Q2 25
$538.6M
$334.5M
Q1 25
$540.2M
$325.0M
Q4 24
$514.8M
$338.8M
Q3 24
$540.2M
$367.0M
Q2 24
$560.7M
$406.2M
Q1 24
$568.3M
$438.0M
Total Assets
ACTG
ACTG
ZYME
ZYME
Q4 25
$771.0M
Q3 25
$768.9M
$397.3M
Q2 25
$775.5M
$408.4M
Q1 25
$801.6M
$425.5M
Q4 24
$756.4M
$463.1M
Q3 24
$707.6M
$487.2M
Q2 24
$753.6M
$515.6M
Q1 24
$631.7M
$553.8M
Debt / Equity
ACTG
ACTG
ZYME
ZYME
Q4 25
0.17×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACTG
ACTG
ZYME
ZYME
Operating Cash FlowLast quarter
$75.2M
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
22.01×
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACTG
ACTG
ZYME
ZYME
Q4 25
$75.2M
Q3 25
$9.5M
$-31.4M
Q2 25
$50.1M
$12.1M
Q1 25
$2.4M
$-3.4M
Q4 24
$50.1M
$-41.5M
Q3 24
$-593.0K
$-5.9M
Q2 24
$16.1M
$-25.0M
Q1 24
$54.8M
$-37.7M
Free Cash Flow
ACTG
ACTG
ZYME
ZYME
Q4 25
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$335.0K
$-3.4M
Q4 24
$-98.5M
$-41.8M
Q3 24
$-2.8M
$-6.8M
Q2 24
$-126.7M
$-25.6M
Q1 24
$54.6M
$-37.9M
FCF Margin
ACTG
ACTG
ZYME
ZYME
Q4 25
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
0.3%
-12.6%
Q4 24
-201.8%
-134.8%
Q3 24
-12.1%
-42.4%
Q2 24
-490.5%
-133.0%
Q1 24
224.4%
-377.5%
Capex Intensity
ACTG
ACTG
ZYME
ZYME
Q4 25
Q3 25
1.5%
Q2 25
1.1%
Q1 25
1.7%
0.1%
Q4 24
304.4%
1.0%
Q3 24
9.6%
5.6%
Q2 24
553.0%
3.1%
Q1 24
1.1%
1.8%
Cash Conversion
ACTG
ACTG
ZYME
ZYME
Q4 25
22.01×
Q3 25
Q2 25
5.21×
Q1 25
0.10×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACTG
ACTG

Energy Operations$16.0M32%
Transportation Safety$10.4M21%
Office Storage And Display Solutions$8.4M17%
Printers Consumables And Parts$6.5M13%
Natural Gas Reserves$5.1M10%
Natural Gas Liquids Reserves$3.3M7%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons